Monopar Therapeutics Inc <MNPR.OQ> expected to post a loss of 42 cents a share - Earnings Preview
Monopar Therapeutics Inc MNPR.OQ MNPR.O is expected to show no change in quarterly revenue when it reports results on March 26 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Monopar Therapeutics Inc is for a loss of 42 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Monopar Therapeutics Inc is $38.50, below its last closing price of $40.00.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.48 | -0.48 | -0.37 | Beat | 22.4 |
Jun. 30 2024 | -0.47 | -0.47 | -0.50 | Missed | -7.1 |
Mar. 31 2024 | -0.60 | -0.60 | -0.50 | Beat | 16.7 |
Dec. 31 2023 | -0.77 | -0.60 | Beat | 22.6 | |
Sep. 30 2023 | -0.75 | -0.85 | -0.70 | Beat | 17.6 |
Jun. 30 2023 | -0.89 | -0.92 | -0.80 | Beat | 13 |
Mar. 31 2023 | -1.11 | -1.11 | -0.95 | Beat | 14.4 |
Dec. 31 2022 | -1.02 | -1.02 | -1.15 | Missed | -12.2 |
This summary was machine generated March 24 at 12:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
Silver Plunges 10%, Gold Tests $4,900: Is the Bull Market Over Ahead of CPI?
TradingKey - Ahead of the release of the U.S. January CPI report, financial markets experienced a sudden broad sell-off on Thursday. Alongside a sharp decline in U.S. equities, prices for commodities such as gold (XAUUSD) also plummeted. Gold dropped nearly $200 within a 30-minute window, a decline
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?
This $1 Trillion AI Stock Is Getting Ready for 2026: Is Meta a Good Buy?
When ads and commerce are factored in, Meta is building a long-term platform—in Augmented Reality and smart glasses — to get us closer to the future of AI. This device hardware business is less profitable than ads right now, but it could grow the company’s ecosystem and open up new ways for it to ma
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.
